Bristol Myers Squibb Company (NYSE:BMY – Get Free Report) Director Julia Haller sold 3,800 shares of Bristol Myers Squibb stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the sale, the director directly owned 30,279 shares in the company, valued at approximately $1,916,963.49. The trade was a 11.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Bristol Myers Squibb Stock Up 0.1%
NYSE BMY opened at $62.20 on Monday. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. The company has a market capitalization of $127.15 billion, a P/E ratio of 13.79, a P/E/G ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a one year low of $45.26 and a one year high of $68.64. The stock has a 50 day moving average price of $62.34 and a 200-day moving average price of $60.11.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The firm had revenue of $13.07 billion during the quarter, compared to analyst estimates of $12.72 billion. During the same period last year, the firm posted $1.63 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 6.9% compared to the same quarter last year. As a group, equities analysts predict that Bristol Myers Squibb Company will post 6.45 EPS for the current fiscal year.
Bristol Myers Squibb Dividend Announcement
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on BMY. Roth Capital initiated coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “buy” rating and a $75.00 target price on the stock. William Blair reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 12th. Guggenheim reiterated a “buy” rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Royal Bank Of Canada reissued a “sector perform” rating on shares of Bristol Myers Squibb in a research note on Monday, October 19th. Finally, Wells Fargo & Company decreased their price objective on Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating on the stock in a research report on Tuesday, October 13th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $65.46.
Get Our Latest Stock Analysis on Bristol Myers Squibb
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Financial Freedom LLC acquired a new stake in Bristol Myers Squibb in the 3rd quarter worth about $26,000. Davis Asset Management L.P. acquired a new position in shares of Bristol Myers Squibb during the second quarter valued at approximately $27,000. Addison Advisors LLC acquired a new position in shares of Bristol Myers Squibb during the second quarter valued at approximately $32,000. William Mack & Associates Inc. purchased a new position in shares of Bristol Myers Squibb in the third quarter valued at approximately $35,000. Finally, Groupe la Francaise lifted its position in shares of Bristol Myers Squibb by 562.9% in the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 501 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.
Bristol Myers Squibb News Roundup
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
- Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
- Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
- Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
- Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.
The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.
Featured Stories
- Five stocks we like better than Bristol Myers Squibb
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
